stockrowEli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
Follow LLY
Alert me
Eli Lilly and Company (LLY) Revenue
Eli Lilly and Company's revenue for fiscal 2025 was $65.2B, up 44.7% from $45.0B in fiscal 2024. Over the twelve months to 30 September 2026 it was $86.5B. Over the past ten years it has ranged from $20.0B (fiscal 2015) to $65.2B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 8 consecutive fiscal years. Eli Lilly and Company ranks 2nd of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $65.2B | 44.70% |
| FY2024 | $45.0B | 32.00% |
| FY2023 | $34.1B | 19.56% |
| FY2022 | $28.5B | 0.79% |
| FY2021 | $28.3B | 15.40% |
| FY2020 | $24.5B | 9.95% |
| FY2019 | $22.3B | 3.84% |
| FY2018 | $21.5B | 7.61% |
| FY2017 | $20.0B | (5.88%) |
| FY2016 | $21.2B | 6.33% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $24.4B | 6.19% |
| Jun 2026 | $23.0B | 16.04% |
| Mar 2026 | $19.8B | 2.63% |
| Dec 2025 | $19.3B | 9.60% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| JNJ Johnson & Johnson compare | $99.3B |
| LLY Eli Lilly and Company | $86.5B |
| MRK Merck & Co., Inc. compare | $67.4B |
| ABBV AbbVie Inc. compare | $66.0B |
| PFE Pfizer Inc. compare | $63.6B |
| AZN AstraZeneca PLC compare | $62.4B |
| NVS Novartis AG compare | $57.4B |
| AMGN Amgen Inc. compare | $38.9B |
| GILD Gilead Sciences, Inc. compare | $31.0B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on LLY
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement